Skip to main content
. 2018 Nov 26;36(3):569–578. doi: 10.1007/s10815-018-1377-0

Table 4.

Baseline characteristics according to the number of mature oocytes retrieved (≥ 10 vs < 10) in the whole cohort and in the subgroup of women undergoing proper random start

Characteristics Whole cohort Proper random start
≥ 10 < 10 p ≥ 10 < 10 p
Number 35 37 25 27
Age (years) 30.1 ± 5.1 32.6 ± 5.8 0.06 30.2 ± 4.6 33.6 ± 5.5 0.02
BMI (kg/m2) 22.4 ± 3.9 21.0 ± 3.2 0.09 22.3 ± 3.7 20.9 ± 3.0 0.14
Previous deliveries 4 (11%) 3 (8%) 0.71 2 (8%) 3 (11%) 1.00
Menstrual cycle duration (days) 0.30 0.31
 24–27 3 (9%) 7 (19%) 2 (8%) 5 (19%)
 28–32 25 (71%) 26 (70%) 17 (68%) 19 (70%)
 > 32 7 (20%) 4 (11%) 6 (24%) 3 (11%)
Serum AMH (ng/ml) 3.7 (2.2–5.2) 1.4 (0.6–2.6) < 0.001 3.7 (2.3–5.0) 1.4 (0.6–1.9) < 0.001
Total AFC 23.5 ± 11.0 14.1 ± 8.1 < 0.001 24.9 ± 12.0 14.4 ± 7.8 < 0.001
Indication to oocyte cryopreservation 0.73 0.98
 Breast cancer 20 (57%) 22 (60%) 15 (60%) 17 (63%)
 Lymphoma 11 (31%) 9 (24%) 7 (28%) 7 (26%)
 Others 4 (11%) 6 (16%) 3 (12%) 3 (11%)
Ovarian cysts 2 (6%) 2 (5%) 1.00 1 (4%) 2 (7%) 1.00
Cycle phase at referral 0.45 1.00
 Estroprogestins 2 (6%) 4 (11%) 0 (0%) 0 (0%)
 Follicular phase 19 (54%) 15 (40%) 11 (44%) 11 (41%)
 Luteal phase 14 (40%) 18 (49%) 14 (56%) 16 (59%)
Canceled cycles (poor response) 0 (0%) 3 (8%) 0.24 0 (0%) 3 (11%) 0.24
Drugs used a
 Corrifollitropin 100–150 mcg 35 (100%) 34 (100%) 25 (100%) 24 (100%)
 Total dose of recombinant FSH (IU) 1423 ± 1092 1924 ± 1109 0.10 1530 ± 1198 2038 ± 1175 0.18
 Total N of GnRH antagonist ampoules 5.6 ± 1.2 5.0 ± 1.4 0.06 5.8 ± 1.1 5.0 ± 1.5 0.05
Duration of stimulation (days)a 11.3 ± 1.5 11.6 ± 2.1 0.49 11.4 ± 1.2 11.7 ± 2.2 0.49
N of developed follicles (diameter ≥ 11 mm)a 25.6 ± 9.9 13.1 ± 5.2 < 0.001 26.4 ± 10.0 12.9 ± 5.1 < 0.001
N of oocytes retrieved 21.8 ± 8.1 7.5 ± 4.6 < 0.001 22.8 ± 7.7 7.2 ± 4.8 < 0.001
N of mature oocytes retrieved (frozen) 16.9 ± 6.3 4.6 ± 3.1 < 0.001 17.8 ± 5.9 4.6 ± 3.2 < 0.001

aExcluding canceled cycles